KUALA LUMPUR, Oct 28 – In-vitro diagnostics, or diagnostic testing done outside the body, influence over 60 per cent of clinical decisions but comprise only about 2 per cent of total health care spending in the clinical setting worldwide, Roche said.
The pharmaceutical multinational corporation also rolled out in Malaysia a new “cobas pro integrated solutions”, which aim to aid laboratories manage a large amount of patient samples and provide high quality results in a shorter time frame, on top of needing minimal operator intervention.
“The health care environment today is characterised by the rising burden of chronic diseases, an ageing population but also escalating health care costs,” Roche Diagnostics Malaysia general manager Heng Chai Yin said during the inaugural Roche Innovation Day.
“Our aim is to work alongside laboratories and other healthcare providers to address these challenges so that together we can realise our vision of improving the lives of patients. We remain as committed today as we did when we first launched our operations in Malaysia, more than 20 years ago.
“With the prevalence of non-communicable diseases such as cardiovascular diseases being on the rise in Malaysia, we are working closely with government and private health care institutions and diagnostics labs across the country to provide innovative diagnostics solutions which can help save lives,” Heng said.
Ipsos Healthcare Asia Pacific director Hannah Osborn said preventive and precision medicine were increasingly popular, with people now becoming highly informed and engaged in managing their own health.
“Smart health care is delivering cost effective patient centric care through a shift towards online health care, digital health records, and population health management solutions,” she said.
“The future of health diagnostics is being driven by automation, robotics, artificial intelligence, and real-world evidence, which improve productivity, speed, and accuracy, and unlocks the value in health care.”
Roche Diagnostics Malaysia specialises in a broad spectrum of diagnostic areas including: clinical chemistry and immunoassays, molecular diagnostics, tissue diagnostics, point-of-care diagnostics, laboratory automation & IT; and solutions for life science and diabetes care.
